WHO ICTRP trial
ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia
EUCTR2019-004055-37-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2019-004055-37-ES |
|---|---|
| Public title | ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia |
| Scientific title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia |
| Primary sponsor | Alexion Pharmaceuticals, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Taiwan;Spain;Russian Federation;Italy;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Korea, Republic of |
| Conditions | WAIHA MedDRA version: 20.0 Level: LLT Classification code 10003825 Term: Autoimmune hemolytic anemia System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] |
| Interventions | Product Code: ALXN1830 Pharmaceutical Form: Solution for infusion INN or Proposed INN: ORILANOLIMAB CAS Number: 2066544-85-0 Current Sponsor code: ALXN1830 Other descriptive name: SYNT001 Concentration unit: mg/ml milligram(s)/millilitre… |
| Registration date | Oct 5, 2020 |
| Target size | 32 |
| Secondary IDs | ALXN1830-WAI-201 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: